---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-062337"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:54:04.700358+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Longeveron receives FDA clearance for Phase 2 trial of laromestrocel in pediatric dilated cardiomyopathy

## Summary
- FDA approved IND for a Phase 2 pivotal registration study of laromestrocel for pediatric DCM.
- Trial initiation anticipated in first half of 2026.
- Nearly 40% of children with DCM require heart transplant or die within 2 years of diagnosis.
- Allogeneic mesenchymal stem cell therapy may address anti-inflammatory and pro-vascular mechanisms.

## SEC filing metadata
- accession: 0001213900-25-062337
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000121390025062337/0001213900-25-062337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000121390025062337/ea0248389-8k_longeveron.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-062337
- JSON: https://secwatch.observer/filing/0001213900-25-062337.json
- Plain text: https://secwatch.observer/filing/0001213900-25-062337.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.